Sectors
ENGN
enGene Therapeutics Inc.
1.91
2 x 1.34
2 x 2.43
bid
ask
+
0.00
0.17%
10:06 AM
timesize
| Ytd | -78.81% | |
| 1y | -71.95% |
1.91
day range
1.92
1.40
52 week range
12.25
| Open | 1.92 | Prev Close | 1.91 | Low | 1.91 | High | 1.92 | Mkt Cap | 128.22M |
| Vol | 19.34K | Avg Vol | 828.16K | EPS | -2.07 | P/E | N/A | Forward P/E | -3.53 |
| Beta | -0.28 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-08 | 50-d Avg | 1.83 | 200-d Avg | 5.39 | 1yr Est | 27.00 |
| Income Statement | |||
| Operating Expenses | 34.01M | ||
| Research and Development Expense | 20.09M | ||
| Selling, General and Administrative Expense | 13.92M | ||
| Operating Income | -34.01M | ||
| Interest Expense | 843.00K | ||
| Net Income | -32.50M | ||
| Net Income Common Stock | -32.50M | ||
| Net Income Common Stock (USD) | -32.50M | ||
| Consolidated Income | -32.50M | ||
| Earnings per Basic Share | -0.47 | ||
| Earnings per Basic Share (USD) | -0.47 | ||
| Earnings per Diluted Share | -0.47 | ||
| Earning Before Interest & Taxes (EBIT) | -31.66M | ||
| Earning Before Interest & Taxes (USD) | -31.66M | ||
| Weighted Average Shares | 69.73M | ||
| Weighted Average Shares Diluted | 69.73M | ||
| Balance Sheet | |||
| Cash and Equivalents | 41.03M | ||
| Cash and Equivalents (USD) | 41.03M | ||
| Investments | 225.37M | ||
| Investments Current | 225.37M | ||
| Current Assets | 277.90M | ||
| Property, Plant & Equipment Net | 9.03M | ||
| Total Assets | 288.32M | ||
| Debt Current | 2.45M | ||
| Total Debt | 33.27M | ||
| Current Liabilities | 27.21M | ||
| Debt Non-Current | 30.82M | ||
| Total Liabilities | 58.03M | ||
| Accumulated Retained Earnings (Deficit) | -464.51M | ||
| Accumulated Other Comprehensive Income | -1.35M | ||
| Shareholders Equity | 230.29M | ||
| Shareholders Equity (USD) | 230.29M | ||
| Assets Non-Current | 10.42M | ||
| Total Debt (USD) | 33.27M | ||
| Liabilities Non-Current | 30.82M | ||
| Trade and Non-Trade Payables | 2.54M | ||
| Tax Assets | 975.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 405.00K | ||
| Net Cash Flow from Financing | 23.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 11.20M | ||
| Issuance (Purchase) of Equity Shares | 23.00K | ||
| Net Cash Flow from Investing | 30.12M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 30.12M | ||
| Net Cash Flow from Operations | -18.95M | ||
| Share Based Compensation | 7.81M | ||